Curnutte John T. - 05 Jun 2025 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Reporting relationship: Director
Issuer ticker: PLRX
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2025, 20:44:11 UTC
Prior SEC filing: 17 Jun 2024
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Woo, attorney-in-fact

Key filing fact

Curnutte John T. filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 09 Jun 2025.

Key facts

This page summarizes Curnutte John T.'s Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2025, 20:44.

Change

Previous filing in this sequence was filed on 17 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001574589 Primary reporting owner

Curnutte John T

Relationship: Director
Address: C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO
Signature: /s/ Jennifer Woo, attorney-in-fact
Signature date: 09 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLRX transaction Derivative

Common Stock (Right to Buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $1.61
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.